Figure 3. Target Lesion Size, Best Percentage Change Waterfall Plot by BICR In 27 Patients Treated With Savolitinib and 24 Treated With Sunitinib^a.

BICR indicates blinded independent central review.

^aNine patients (savolitinib n = 6; sunitinib n = 3) were not included in the target lesion size plot: no target lesions present at baseline that were selected as target lesions for the purpose of BICR assessment (n = 7: savolitinib n = 5, sunitinib n = 2); no postbaseline target lesion assessment captured (savolitinib n = 1; sunitinib n = 1).